These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3260565)

  • 1. Generation of LAK cells depends on the age of LAK cell precursor donors.
    Indrová M; Bubeník J
    Folia Biol (Praha); 1988; 34(1):48-52. PubMed ID: 3260565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B; Rees RC
    Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells.
    Lowrey DM; Hameed A; Lichtenheld M; Podack ER
    Cancer Res; 1988 Aug; 48(16):4681-8. PubMed ID: 3260817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
    Indrová M; Bubeník J; Toulcová A
    Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice.
    Radzikowski C; Rygaard J; Budzynski W; Stenvang JP; Schou M; Vangsted A; Zeuthen J
    APMIS; 1994 Jul; 102(7):481-8. PubMed ID: 7917216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
    Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
    Beckner SK; Maluish AE; Longo DL
    Cancer Res; 1987 Oct; 47(20):5504-8. PubMed ID: 3498534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus.
    Ballas ZK; Rasmussen W
    J Immunol; 1987 Nov; 139(10):3542-9. PubMed ID: 3500221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The precursor cells of mouse lymphokine-activated killer (LAK) cells.
    Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
    Thymus; 1987; 9(3):131-9. PubMed ID: 3495912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.